Table 2. Distribution of Metastatic Tumors According to Organs and Systems and Mortality Status of These Cases .

Organ	Number of cases (%)	Ex	Alive	System	Number of cases (%)	Ex	Alive
Colon	37 (14.2%)	31 (83.8%)	6 (16.2%)	Gastrointestinal tract	48 (18.5%)	41 (85.4%)	7 (14.6%)
Stomach	8 (3.1%)	7 (87.5%)	1 (12.5%)
Small intestine	2 (0.8%)	2 (100.0%)	0 (0.0%)
Esophagus	1 (0.4%)	1 (100.0%)	0 (0.0%)
Pancreas	49 (18.8%)	44 (89.8%)	5 (10.2%)	Pancreatobiliary system	53 (20.4%)	48 (90.6%)	5 (9.4%)
Gallbladder	4 (1.5%)	4 (100.0%)	0 (0.0%)
Lung	49 (18.8%)	47 (95.9%)	2 (4.1%)	Respiratory system	50 (19.2%)	48 (96.0%)	2 (4.0%)
Larynx	1 (0.4%)	1 (100.0%)	0 (0.0%)
Breast	40 (15.4%)	26 (65.0%)	14 (35.0%)	Breast	40 (15.4%)	26 (65.0%)	14 (35.0%)
Tuba/ovary	7 (2.7%)	5 (71.4%)	2 (28.6%)	Female genital system	10 (3.8%)	8 (80.0%)	2 (20.0%)
Endometrium	2 (0.8%)	2 (100.0%)	0 (0.0%)
Cervix	1 (0.4%)	1 (100.0%)	0 (0.0%)
Bladder	4 (1.5%)	4 (100.0%)	0 (0.0%)	Urinary system	9 (3.5%)	9 (100.0%)	0 (0.0%)
Kidney	4 (1.5%)	4 (100.0%)	0 (0.0%)
Prostate	1 (0.4%)	1 (100.0%)	0 (0.0%)
Skin	4 (1.5%)	2 (50.0%)	2 (50.0%)	Skin	4 (1.5%)	2 (50.0%)	2 (50.0%)
Peritoneum	1 (0.4%)	1 (100.0%)	0 (0.0%)	Mesothelium	1 (0.4%)	1 (100.0%)	0 (0.0%)
Lymphoma	7 (2.7%)	7 (100.0%)	0 (0.0%)	Lymphoid system	7 (2.7%)	7 (100.0%)	0 (0.0%)
Unknown primary	38 (14.6%)	38 (100.0%)	0 (0.0%)	Unknown primary	38 (14.6%)	38 (100.0%)	0 (0.0%)
Overall	260 (100%)	228 (87.7%)	32 (12.3%)	Overall	260 (100%)	228 (87.7%)	32 (12.3%)